Table 1.
Characteristics of patients with confirmed TP53 mutations.
| Characteristic | Clinical Trial | |
|---|---|---|
| Ixazomib + Vorinostat (n = 59) | Pazopanib + Vorinostat (n = 11) | |
| Median age (range), years | 59 (24–76) | 70 (46–78) |
| Gender | ||
| Male | 24 (41) | 5 (45) |
| Female | 35 (59) | 6 (55) |
| Race | ||
| White | 46 (78) | 9 (82) |
| Hispanic | 5 (8) | 0 |
| African American | 4 (7) | 0 |
| Asian | 4 (7) | 2 (2) |
| ECOG performance status score | ||
| 0 | 11 (19) | 0 |
| 1 | 44 (74) | 11 (100) |
| 2 | 4 (7) | 0 |
| Disease type | ||
| Colorectal cancer | 20 (34) | 3 (27) |
| Ovarian cancer | 14 (23) | 3 (27) |
| Breast cancer | 4 (7) | 1 (9) |
| Sarcoma | 4 (7) | 2 (18) |
| Head and neck cancer | 4 (7) | 1 (9) |
| Others* | 13 (22) | 1 (9) |
| Prior chemotherapy | ||
| Median no. of regimens (range) | 5 (0–9) | 4 (0–10) |
| VEGF inhibition−based therapy | 34 (58) | 5 (45) |
| Prior radiation therapy | 33 (56) | 3 (27) |
| Prior surgery | 47 (80) | 10 (91) |
| Median no. of metastasis sites (range) | 3 (1–5) | 3 (2–5) |
| TP53 point mutations | 50 (85) | 9 (82) |
| TP53 hotspot mutations# | 24 (41) | 4 (36) |
| TP53 non-point mutations | 9 (15) | 2 (18) |
Note: All data are no. of patients (%) unless otherwise noted.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor.
*Includes duodenal, gastric, and pancreatic cancer (n = 2 each) and esophageal cancer, endometrial cancer, non-small cell lung cancer, renal cancer, urachal adenocarcinoma, melanoma, and Mullerian tumor (n = 1 each).
#Mutations at R175, G245, R248, R249, R273, or R282.